Skip to main content

A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer (TNBC

Clinical Trial Grant
Duke Scholars

Administered By

Duke Cancer Institute

Awarded By

Merck Sharp & Dohme

Start Date

July 7, 2017

End Date

December 28, 2018
 

Administered By

Duke Cancer Institute

Awarded By

Merck Sharp & Dohme

Start Date

July 7, 2017

End Date

December 28, 2018